SFTSV belongs to the genus Bandavirus in the family Phenuiviridae and was first identified in China in 2009 after outbreaks of a mysterious febrile illness characterized by severe thrombocytopenia, leukopenia and, in a substantial fraction of cases, multi-organ failure. Case fatality rates in hospitalized patients have been reported in the range of several percent to more than ten percent depending on the region and cohort, and the virus has since been documented in South Korea, Japan, Vietnam and Taiwan. The pathogen circulates silently in a wide range of animals, including domestic livestock and wild mammals, with ticks of the genus Haemaphysalis serving as principal vectors. Because human infections often begin with nonspecific fever and gastrointestinal complaints, clinicians need a rapid differential diagnosis, particularly in areas where other tick-borne diseases such as scrub typhus and spotted fever rickettsiosis co-circulate. Serological assays, meanwhile, are of limited use in the acute phase because antibodies take days to appear.

The new study targeted the Gn glycoprotein, one of the two mature subunits derived from the viral envelope precursor protein. Gn sits on the virion surface alongside its partner Gc and plays a central role in receptor binding and entry, making it an attractive antigen for immunodiagnostic capture. The researchers generated a panel of monoclonal antibodies against Gn and then systematically characterized each clone for immunoglobulin isotype, the epitope it recognizes, its binding affinity for the antigen and its efficiency at capturing intact virus. This characterization step is critical in lateral flow development because the assay depends on a carefully choreographed sandwich: one antibody, labeled with a visible reporter, binds the antigen in the sample, and a second antibody, immobilized in a thin line on the nitrocellulose membrane, catches the resulting complex so that it accumulates as a readable band.

From the panel, the team selected a monoclonal antibody with strong Gn recognition and antigen-capturing activity to serve as the detection antibody, conjugating it to magnetic nanoparticles that function as the visual reporter. Three additional antibodies were deployed as capture antibodies on the test line, a design choice intended to broaden the range of antigen conformations and epitopes that can be caught, thereby improving the chance that divergent viral strains or partially degraded antigen will still register. The use of multiple capture antibodies is a common strategy for coping with the genetic diversity of SFTSV, which is divided into several genotypes distributed across different geographic regions. A test that recognizes only one genotype risks false negatives in neighboring countries where another lineage predominates.

The magnetic nanoparticles themselves are the key innovation relative to conventional gold-nanoparticle lateral flow strips. Because the particles are superparamagnetic, the antibody-particle conjugates can be concentrated at the test line with an external magnet, and the resulting signal can be read either visually or with inexpensive magnetic readers, improving sensitivity without the cost of fluorescent or enzymatic detection systems. Magnetic labels are also less prone to interference from the colored constituents of blood and serum, an advantage when testing samples from animals whose sera may be hemolyzed or lipemic. In the reported configuration, the assay detected as little as 20 nanograms of recombinant Gn protein or approximately five times ten to the fifth focus-forming units of SFTSV within 45 minutes, all without requiring any specialized instrumentation at the point of care.

A notable strength of the study is the breadth of expression systems and host species used to validate the assay. The Gn-LFA detected recombinant Gn proteins produced in both mammalian and plant expression platforms, confirming that the antibodies recognize epitopes that survive different glycosylation patterns and folding environments. Plant-based expression is increasingly attractive for diagnostic reagent production because it is fast, scalable and inexpensive, and demonstrating cross-platform compatibility suggests the assay could be manufactured at low cost in the regions that need it most. The team also demonstrated compatibility across sera from multiple host species, an important property for One Health surveillance programs that screen cattle, goats, dogs, cats and wildlife in addition to suspected human cases. A single test format that works across species simplifies logistics considerably compared with assays that must be re-optimized for each animal’s immunoglobulin background.

The implications extend beyond the clinic. Because SFTSV infects ticks and a broad range of vertebrate hosts without causing obvious disease in most of them, the true geographic footprint of the virus is almost certainly wider than the map of confirmed human cases suggests. Veterinary and public health authorities need tools that can be carried into farms, slaughterhouses and field stations to sample animals quickly and cheaply. A lateral flow strip that returns a result in three-quarters of an hour, at a per-test cost measured in a few dollars, could transform the granularity of surveillance data, allowing health officials to detect viral circulation in a region before the first human cluster appears. The authors frame their work explicitly as proof of concept for such applications, positioning the Gn-LFA within the One Health paradigm that links human, animal and environmental health monitoring.

Several caveats remain before the assay can move into routine use. The sensitivity reported here, while adequate for a rapid screening tool, is below that of real-time RT-PCR, so negative results in suspected human cases would still warrant confirmatory molecular testing, particularly early in infection when viremia may be low. Field validation with large panels of clinical samples from endemic areas, including samples containing other tick-borne pathogens that could provoke cross-reactivity, will be essential to establish specificity in real-world matrices. The study was published as an open-access paper that has been shared early to provide faster access to peer-reviewed, accepted research, and the published version remains subject to further editorial processing. The work was funded by the National Science and Technology Council of Taiwan with additional support from the Ministry of Education’s Higher Education Sprout Project, and the authors declare no competing interests.

Even so, the study adds a concrete new tool to the diagnostic arsenal against an emerging virus for which no approved antiviral therapy or widely deployed human vaccine yet exists. Monoclonal antibodies against Gn could also find secondary uses in research and development, from antigen-capture ELISAs to immunohistochemistry and the characterization of viral glycoprotein processing. As SFTSV continues its quiet expansion across tick populations in Asia, and as related bandaviruses are discovered elsewhere in the world, the ability to detect viral antigen rapidly, cheaply and in the field will only grow in importance. The Taiwanese-led team’s combination of a well-characterized antibody panel, magnetic nanoparticle labeling and multi-epitope capture offers a template that other groups studying emerging tick-borne viruses may well follow.

Subject of Research: Development of monoclonal antibodies and a magnetic nanoparticle lateral flow assay for rapid detection of severe fever with thrombocytopenia syndrome virus

Article Title: Development of anti-Gn monoclonal antibodies for magnetic nanoparticle-coupled lateral flow detection of severe fever with thrombocytopenia syndrome virus

Article References: Development of anti-Gn monoclonal antibodies for magnetic nanoparticle-coupled lateral flow detection of severe fever with thrombocytopenia syndrome virus. (n.d.). https://doi.org/10.1186/s12985-026-03329-5

Image Credits: AI Generated

DOI: 10.1186/s12985-026-03329-5

Keywords: SFTSV, Gn glycoprotein, monoclonal antibodies, lateral flow assay, magnetic nanoparticles, diagnostics, tick-borne virus, One Health, point-of-care testing, zoonosis, viral surveillance, antigen detection